Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05583149 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Results first posted: Jan 29, 2026v5
  2. Re-verified, no change to tracked fieldsv4
  3. Trial status: Recruiting to Active, Not Recruitingv3 Show 5 more changesShow less
    • Enrollment target: estimated 27 to confirmed 28
    • Primary completion date changed from estimate of Mar 1, 2025 to Nov 23, 2024
    • Secondary endpoints revised (15)
    • Primary endpoint revised
    • Site details revised at 2 of 2 sites
  4. Lead sponsor: Jeremy Abramson, MD to Patrick C. Johnson, MDv2 Show 5 more changesShow less
    • Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Sep 1, 2024 to Mar 1, 2025
    • Start date changed from estimate of Oct 2022 to Mar 1, 2023
    • Study completion date: Sep 1, 2029 to Mar 1, 2029
    • Site details revised at 2 of 2 sites
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma. This research study involves the study drug acalabrutinib in combination with lisocabtagene maraleuce
Trial Details
NCT Number NCT05583149
Lead Sponsor Patrick C. Johnson, MD
Collaborators: AstraZeneca
Conditions
(from sponsor)		 Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL), De Novo or Transformed Indolent B-cell Lymphoma, DLBCL, Nos Genetic Subtypes, T Cell/Histiocyte-rich Large B-cell Lymphoma, EBV-Positive DLBCL, Nos +5 more
Related terms Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov